logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10933072 B1

PDFFull Text
Date of Patent:
Mar. 02, 2021

Filed:

Oct. 30, 2019

Treating and preventing disease with tma and tmao lowering agents

Applicant:

The Cleveland Clinic Foundation, Cleveland, OH (US);

Inventor:

Stanley L. Hazen, Pepper Pike, OH (US);

Assignee:

The Cleveland Clinic Foundation, Cleveland, OH (US);

Attorneys:

Casimir Jones, S.C.

Jason R. Bond

Primary Examiner:

Ernst V Arnold

Int. Cl.
CPC ...
A61K 31/14 (2006.01); A61P 13/12 (2006.01); A61P 9/00 (2006.01); A61K 31/616 (2006.01); A61K 31/13 (2006.01); A61K 31/133 (2006.01); A61K 31/205 (2006.01); A61K 31/4164 (2006.01); A61K 31/43 (2006.01); A61K 31/4365 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/409 (2006.01); A61K 33/44 (2006.01); G01N 33/49 (2006.01); A61K 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/616 (2013.01); A61K 31/00 (2013.01); A61K 31/13 (2013.01); A61K 31/133 (2013.01); A61K 31/205 (2013.01); A61K 31/409 (2013.01); A61K 31/4164 (2013.01); A61K 31/43 (2013.01); A61K 31/4365 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/675 (2013.01); A61K 33/44 (2013.01); A61P 9/00 (2018.01); A61P 13/12 (2018.01); G01N 33/492 (2013.01); G01N 2800/32 (2013.01); G01N 2800/34 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

Find Patent Forward Citations

Loading…